None listed
Conditions
Brief summary
Soluble fibre is a source of plasma short chain fatty acids (SCFA), which are known to have antiinflammatory properties. This study will investigate the plasma short chain fatty acid (SCFA) yield over 10 hours following consumption of two different oligosaccharide blends in healthy adult males and females. This information will be used in the design of future clinical intervention trials.
Interventions
This is a double-blinded, randomised, 2-way crossover trial. Participants are required to attend 2 clinic visits. At each clinic visit participants will be randomly allocated to consume one of 2 treatments (2 different soluble fibre formulations, containing 12g of different types of oligosaccharides), plus 2 slices of white bread and 250ml water (room temperature). Study meals will be consumed in random order, with a minimum one-week washout period between clinic visits. Adherence to the intervention will be monitored by direct observation by study personnel. In the two days prior to the scheduled appointments, participants will consume fibre-controlled background diet. This will include consumption of no more than 3 serves of fruits and vegetables combined per day, and avoidance of other high soluble fibre content foods including oats, legumes (kidney, navy, lima, baked beans), wholegrain bread and cereal products. Participants will be provided with a standardised non-fermentable evening meal (lasagna), which they will be asked to consume the night before each of their scheduled appointments. They will also be asked to fast for 12-hours prior to the clinic visit.
Sponsors
Study design
Eligibility
Inclusion criteria
Males and Females Aged 18+ years
Exclusion criteria
Body mass index (BMI)>= 3okg/m2; nutritional, fibre or probiotic supplement use within the previous 4 weeks; current smokers; pregnancy or breastfeeding; chronic or excessive alcohol consumption; unexplained weight loss (>5% body weight) in the past 6 months; diagnosis of chronic disease, including gastrointestinal, metabolic, liver, cardiovascular and respiratory diseases; current use of anti-inflammatory medications (e.g. corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDS)); terminal illness; participation in a research study within previous 4 weeks.